SB 431542
目录号 : GC11545
SB-431542是一种小分子抑制剂，可以阻止TGF-β受体类型I的内部介导物，从而降低TGF-β1介导的增殖、细胞因子和胶原蛋白表达。
Cas No.:301836-41-9
Sample solution is provided at 25 µL, 10mM.
SB-431542, a small molecule inhibitor of the type I TGF-β receptor, blocks intracellular mediators of TGF-1 signaling, which leads to decreased TGF-β1–mediated proliferation, cytokines and collagen expression. In clinical settings, SB-431542 is widely used to treat respiratory asthma, and inhibits proliferation and synthesis of adventitial fibro in the process of pulmonary vascular remodeling.[1]
In vitro study indicated that SB-431542 is able to inhibit ALK5 with an IC50 of 94 nM and other type I receptors, such as ALK4. Although SB-431542 inhibited ALK4 with an IC50 of 140 nM. Moreover, SB-431542 inhibited TGF-β1–induced collagen Iα1 and PAI-1 mRNA with IC50 values of 60 and 50 nM, respectively. In addition, SB-431542 inhibited TGF-β1–induced fibronectin mRNA and protein with IC50 values of 62 and 22 nM, respectively. These data demonstrate for the first time that ALK5 activity is required for TGF-β1 regulation of extracellular matrix markers FN, collagen Iα1, and PAI-1 mRNA.[1]
In vivo study demonstrated that SB-431542 has the capacity to inhibit TGF-β1-induced gene expression. SB-431542 is recognized as a important inhibitor of the TGF-β1 receptors in blocking TGF-β1/Smads signal pathways in vascular remodeling. Moreover, hypoxia-induced vascular remodeling can significantly increase the amount of cytokines and collagen in vascular adventitia. However, after the treatment of SB-431542, attenuation of the fibrosis promoting effects of TGF-β1, including TGF-β1-induced cell proliferation, cell motility, cell migration and cell synthesis were observed. Therefore, it is significant to the identify the potential of SB-431542 for the treatment of hypoxia-induced pulmonary hypertension.[2]
References:
[1]. Laping NJ, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002 Jul;62(1):58-64.
[2]. Yuan W, et al. SB-431542, a specific inhibitor of the TGF-β type I receptor inhibits hypoxia-induced proliferation of pulmonary artery adventitial fibroblasts. Pharmazie. 2016 Feb;71(2):94-100.
SB-431542是一种小分子抑制剂,可以阻止TGF-β受体类型I的内部介导物,从而降低TGF-β1介导的增殖、细胞因子和胶原蛋白表达。在临床上,SB-431542被广泛用于治疗呼吸性哮喘,并在肺血管重塑过程中抑制外膜成纤维细胞的增殖和合成。[1]
实验室研究表明,SB-431542能够抑制ALK5,IC50为94 nM,并且还能抑制其他类型I受体,如ALK4。虽然SB-431542对ALK4的IC50为140 nM。此外,SB-431542以IC50值分别为60和50 nM抑制了TGF-β1诱导的胶原蛋白Iα1和PAI-1 mRNA。此外,SB-431542以IC50值分别为62和22 nM抑制了TGF-β1诱导的纤维连接蛋白mRNA和蛋白质。这些数据首次证明了ALK5活性对于TGF-β1调节细胞外基质标记物FN、胶原蛋白Iα1和PAI-1 mRNA是必需的。[1]
实验表明,SB-431542具有抑制TGF-β1诱导基因表达的能力。在血管重塑中,SB-431542被认为是TGF-β1受体的重要抑制剂,可以阻断TGF-β1/Smads信号通路。此外,在缺氧诱导的血管重塑中,细胞因子和胶原蛋白的含量显著增加。然而,在使用SB-431542治疗后观察到了减轻TGF-β1促进纤维化作用（包括促进细胞增殖、运动、迁移和合成）的效果。因此,确定SB-431542对治疗缺氧性肺动脉高压潜力具有重要意义。[2]
| Kinase experiment [1]: | |
|
Preparation Method |
The kinase domain without the GS region was cloned and expressed as a GST fusion protein. Expressing the protein without the GS domain, which has been shown to regulate the kinase activity, creates a constitutively active kinase that is able to phosphorylate GST-Smad3. Test the effects of SB-431542 on ALK5 and ALK4 kinase activity with GST-Smad3 as substrate. |
|
Reaction Conditions |
The Kinase assays were performed with 65 nM GSTALK5 and 184 nM GST-Smad3 in 50 mM HEPES, 5 mM MgCl2, 1 mM CaCl2, 1 mM dithiothreitol, and 3 μM ATP. Reactions were incubated with 0.5 μCi of [33P]γATP for 3 h at 30°C. |
|
Applications |
SB-431542 is a selective ALK5 inhibitor with little activity against p38 MAPK. SB-431542 also inhibits ALK4 activity. Which is consistent with the degree of homology between these kinases, such that ALK4 is the closest related kinase to ALK5. This data clearly demonstrated that SB-431542 is a potent and selective inhibitor of ALK5 and ALK4, with slightly higher selectivity for ALK5. |
| Cell experiment [1]: | |
|
Cell lines |
Renal proximal tubule epithelial cells (RPTEC) |
|
Preparation Method |
Cells were grown in Earle’s minimum essential medium supplemented with 10% fetal calf serum, penicillin (5 units/ml), and streptomycin (5 ng/ml). Cells were serum-starved for 24 h before treatment. |
|
Reaction Conditions |
Cells were treated with TGF-β1 (5 ng/ml) plus increasing concentrations of SB-431542 (50, 250, 500, and 700 nM). |
|
Applications |
SB-431542 could be used to evaluate whether ALK5 activity is required for TGF-β1-induced translocation of Smad3. SB-431542 at a concentration of 1 μM significantly reduced the TGF-β1-induced nuclear accumulation of Smad proteins. Thus, SB-431542 selectively inhibits TGF-β1–induced Smad translocation without affecting BMP-induced Smads. |
| Animal experiment [2]: | |
|
Animal models |
Male Sprague-Dawley rats aged 5 weeks, weighing 200-220 g |
|
Preparation Method |
Rats lived in air served as control groups, and rats lived in an air condition incubator containing 10% O2 to simulate chronic hypoxia animal model, and served as model groups. Model groups were treated with daily intraperitoneal injections of the SB-431542 for 28 days. |
|
Dosage form |
10 mg/kg; 20 mg/kg |
|
Applications |
SB-431542 inhibited the proliferative activity as a function of exposure time and concentration. Treated rats with SB-431542 caused more pathological changes in vascular adventitia, and the severity of the changes varied from slight to moderate depending on concentrations. In addition, the pulmonary arteries in the hypoxia-induced model groups had greater amounts of collagen fibers than that of the control groups. In comparison, collagen fibers were significantly reduced after treatment with SB-431542 (P < 0.01). |
|
References: [1]. Laping NJ, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002 Jul;62(1):58-64. [2]. Yuan W, et al. SB-431542, a specific inhibitor of the TGF-β type I receptor inhibits hypoxia-induced proliferation of pulmonary artery adventitial fibroblasts. Pharmazie. 2016 Feb;71(2):94-100. |
|
| Cas No. | 301836-41-9 | SDF | |
| 化学名 | 4-[4-(1,3-benzodioxol-5-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide | ||
| Canonical SMILES | C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5 | ||
| 分子式 | C22H16N4O3 | 分子量 | 384.39 |
| 溶解度 | ≥ 19.2mg/mL in DMSO, ≥ 10.06 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6015 mL | 13.0076 mL | 26.0152 mL |
| 5 mM | 0.5203 mL | 2.6015 mL | 5.203 mL |
| 10 mM | 0.2602 mL | 1.3008 mL | 2.6015 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
